Censo Biotechnologies seeks to enable the discovery and development of new targeted treatments for disease by utilising the power of stem cells to predict how drugs will behave accross a given population.
Censo is a stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking.
The company has the capabilities to generate induced pluripotent stem cells (iPSCs) from large cohorts of individuals and use the potential of these cells to produce many different cell types in the human body.
By developing cell-based models of disease using cells from a diverse range of tissue donors, the company supports the development of new targeted treatments for disease. Its major focus is the generation of novel data on drug efficacy and drug response variation for a given population.
Founded in 2016, through the merger of Roslin Cellab and Roslin Cell Sciences, and has facilities in both Edinburgh and Cambridge, UK.
Roslin Biocentre, Wallace Bldg
Roslin, Midlothian, EH25 9PP United Kingdom